Your browser doesn't support javascript.
loading
Comparing Conventional Chemotherapy to Chronomodulated Chemotherapy for Cancer Treatment: Protocol for a Systematic Review.
Kilgallen, Aoife B; Stibler, Urska; Printezi, Markella I; Putker, Marrit; Punt, Cornelis J A; Sluijter, Joost P G; May, Anne M; van Laake, Linda W.
Afiliación
  • Kilgallen AB; Regenerative Medicine Centre, University Medical Centre Utrecht, Utrecht, Netherlands.
  • Stibler U; Division Heart and Lungs, University Medical Centre Utrecht, Utrecht, Netherlands.
  • Printezi MI; Regenerative Medicine Centre, University Medical Centre Utrecht, Utrecht, Netherlands.
  • Putker M; Division Heart and Lungs, University Medical Centre Utrecht, Utrecht, Netherlands.
  • Punt CJA; Division Heart and Lungs, University Medical Centre Utrecht, Utrecht, Netherlands.
  • Sluijter JPG; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), University Medical Centre Utrecht, Utrecht, Netherlands.
  • May AM; Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, Netherlands.
  • van Laake LW; Regenerative Medicine Centre, University Medical Centre Utrecht, Utrecht, Netherlands.
JMIR Res Protoc ; 9(10): e18023, 2020 Oct 21.
Article en En | MEDLINE | ID: mdl-33084590
ABSTRACT

BACKGROUND:

Chronomodulated chemotherapy aims to achieve maximum drug safety and efficacy by adjusting the time of treatment to an optimal biological time as determined by the circadian clock. Although it is a promising alternative to conventional (non-time-stipulated) chemotherapy in several instances, the lack of scientific consensus and the increased logistical burden of timed administration limit the use of a chronomodulated administration protocol.

OBJECTIVE:

With the goal to increase scientific consensus on this subject, we plan to conduct a systematic review of the current literature to compare the drug safety and efficacy of chronomodulated chemotherapy with those of conventional chemotherapy.

METHODS:

This systematic review will comply with the PRISMA (Preferred Reporting Items for the Systematic Reviews and Meta-Analysis) guidelines. In order to identify relevant studies, we conducted a comprehensive search in PubMed and Embase on May 18, 2020. We included clinical studies that compare either the safety or efficacy of chronomodulated chemotherapy with that of conventional chemotherapy. Potential studies will be reviewed and screened by 2 independent reviewers. Quality assessment will be performed using the National Institutes of Health's Study Quality Assessment Tool (Quality Assessment of Controlled Intervention Studies). Disagreements will be resolved by consulting a third independent reviewer.

RESULTS:

This protocol has received funding, and the search for studies from databases commenced on May 18, 2020. The systematic review is planned to be completed by October 31, 2020.

CONCLUSIONS:

In this systematic review, we will compare drug safety and drug efficacy for cancer patients who were administered either chronomodulated chemotherapy or conventional chemotherapy. Moreover, we will highlight the outcomes and quality of the selected trials for this review. TRIAL REGISTRATION PROSPERO International Prospective Register of Systematic Reviews CRD42020177878; https//tinyurl.com/y53w9nq6. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) PRR1-10.2196/18023.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline / Systematic_reviews Idioma: En Revista: JMIR Res Protoc Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline / Systematic_reviews Idioma: En Revista: JMIR Res Protoc Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos